Koenig, Christa http://orcid.org/0000-0002-9965-5183
Ammann, Roland A. http://orcid.org/0000-0002-1902-2352
Kuehni, Claudia E. http://orcid.org/0000-0001-8957-2002
Roessler, Jochen http://orcid.org/0000-0003-4022-4917
Brack, Eva http://orcid.org/0000-0001-5799-3187
Funding for this research was provided by:
Batzebär foundation
Bernese Foundation for Children and Adolescents with Cancer
Article History
Received: 11 January 2021
Accepted: 19 February 2021
First Online: 3 March 2021
Declarations
:
: The study was conducted in accordance with the Declaration of Helsinki and the principles of Good Clinical Practice. Approval was granted by the local Ethics Committees (Ethikkommission der Universitätskinderkliniken Bern, “Gesuch 1912”, Kantonale Ethikkommission Bern, BASEC-No.: 2019-01919) prior to patient recruitment.
: Patients, if able to judge, and their legal guardians gave written informed consent prior to study entry.
: All patients, if able to judge, and their legal guardians additionally gave written consent that the coded study data will be published.
: Jochen Roessler reports personal fees from Pierre Fabre, Roche, Novartis, SOBI, Bayer, Jazz Pharmaceutical and Servier, all outside the submitted work. The other authors declare no competing interests.